image
Healthcare - Biotechnology - NASDAQ - US
$ 2.88
1.41 %
$ 82.4 M
Market Cap
-0.62
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one OCX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.88 USD, OncoCyte Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one OCX stock under the base case scenario is HIDDEN Compared to the current market price of 2.88 USD, OncoCyte Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one OCX stock under the best case scenario is HIDDEN Compared to the current market price of 2.88 USD, OncoCyte Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart OCX

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
1.88 M REVENUE
25.15%
-61 M OPERATING INCOME
-142.84%
-60.7 M NET INCOME
-118.36%
-20.7 M OPERATING CASH FLOW
11.20%
-512 K INVESTING CASH FLOW
45.06%
20.4 M FINANCING CASH FLOW
67.64%
1.49 M REVENUE
1192.17%
-33.6 M OPERATING INCOME
-148.81%
-33.5 M NET INCOME
-148.36%
-5.35 M OPERATING CASH FLOW
3.55%
-210 K INVESTING CASH FLOW
-141.38%
10.8 M FINANCING CASH FLOW
4349.80%
Balance Sheet OncoCyte Corporation
image
Current Assets 11.8 M
Cash & Short-Term Investments 8.64 M
Receivables 1.61 M
Other Current Assets 1.51 M
Non-Current Assets 23.3 M
Long-Term Investments 0
PP&E 2.76 M
Other Non-Current Assets 20.6 M
24.62 %4.60 %4.30 %7.86 %58.62 %Total Assets$35.1m
Current Liabilities 7.28 M
Accounts Payable 2.28 M
Short-Term Debt 1.3 M
Other Current Liabilities 3.7 M
Non-Current Liabilities 40.1 M
Long-Term Debt 2.37 M
Other Non-Current Liabilities 37.7 M
4.81 %7.82 %5.00 %79.63 %Total Liabilities$47.4m
EFFICIENCY
Earnings Waterfall OncoCyte Corporation
image
Revenue 1.88 M
Cost Of Revenue 1.14 M
Gross Profit 740 K
Operating Expenses 60.6 M
Operating Income -61 M
Other Expenses -378 K
Net Income -60.7 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)2m(1m)740k(61m)(61m)378k(61m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
39.34% GROSS MARGIN
39.34%
-3245.14% OPERATING MARGIN
-3245.14%
-3225.04% NET MARGIN
-3225.04%
494.24% ROE
494.24%
-172.92% ROA
-172.92%
-209.76% ROIC
-209.76%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis OncoCyte Corporation
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -60.7 M
Depreciation & Amortization 1.56 M
Capital Expenditures 0
Stock-Based Compensation 1.75 M
Change in Working Capital 0
Others 36.6 M
Free Cash Flow -20.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets OncoCyte Corporation
image
Wall Street analysts predict an average 1-year price target for OCX of $1.95 , with forecasts ranging from a low of $0.5 to a high of $4.25 .
OCX Lowest Price Target Wall Street Target
0.5 USD -82.64%
OCX Average Price Target Wall Street Target
1.95 USD -32.29%
OCX Highest Price Target Wall Street Target
4.25 USD 47.57%
Price
Max Price Target
Min Price Target
Average Price Target
554444333322221111Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership OncoCyte Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
13 M USD 3
0-3 MONTHS
307 K USD 3
3-6 MONTHS
3.98 M USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 3 weeks ago
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif., April 2, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. prismmediawire.com - 1 month ago
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. globenewswire.com - 1 month ago
OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript OncoCyte Corporation (NASDAQ:OCX ) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - CSO Conference Call Participants Mark Massaro - BTIG Mike Matson - Needham Mason Carrico - Stephens Gabby Woody Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. seekingalpha.com - 1 month ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. prismmediawire.com - 1 month ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million GraftAssure RUO assay launched July 2024 Signed strategic partner and investor, Bio-Rad Laboratories Fully funded clinical kitted product development with $50+ million in equity raises Advanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year. globenewswire.com - 1 month ago
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. globenewswire.com - 1 month ago
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. prismmediawire.com - 1 month ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. globenewswire.com - 2 months ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. prismmediawire.com - 2 months ago
Oncocyte Prices $29.1 Million Equity Offering IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”). prismmediawire.com - 2 months ago
Oncocyte Prices $29.1 Million Equity Offering Proceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial Launch Strategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”). globenewswire.com - 2 months ago
8. Profile Summary

OncoCyte Corporation OCX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 82.4 M
Dividend Yield 0.00%
Description OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Contact 15 Cushing, Irvine, CA, 92618 https://oncocyte.com
IPO Date Dec. 30, 2015
Employees 46
Officers Ms. Andrea Susan James Chief Financial Officer Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer Mr. James Liu Vice President of Accounting, Treasurer, Senior Director, Controller & Principal Accounting Officer Ms. Sandra O'Donald Senior Vice President of Business Operations Dr. Michael D. West Ph.D. Scientific Advisor, Co-Chief Executive Officer of Biotime,Inc. & President of Biotime,Inc. Mr. Joshua Riggs President, Chief Executive Officer & Director Dr. Paul R. Billings FACP, M.D. Consulting Chief Medical Officer Mr. Peter Hong Vice President, General Counsel & Secretary Mr. Yuh-Min Chiang Ph.D. Chief Technology Officer